BPC-157 is one of the most heavily discussed peptides in regenerative biology, with a research footprint that spans gastrointestinal injury, soft-tissue repair, angiogenesis, neurological models, and inflammatory signaling. The compound is a synthetic 15-amino-acid peptide whose sequence traces back to research on a body protection compound originally identified in human gastric juice. Most of the published work sits in preclinical territory, which means animal models and cell culture, with limited human data to draw from.
This article is a research primer, not a beginner overview. It covers how BPC-157 is classified, what its molecular characteristics are, which cellular mechanisms and signaling pathways appear in published work, what experimental models researchers actually use, what methodology questions affect interpretation, and what the evidence can and cannot support. For a broader entry-level discussion of what BPC-157 is, research areas, risks, and legal context, see the companion article on BPC-157 research areas, risks, and legal considerations.
This is a research-only discussion. No dosing, administration, or protocol information appears here.
Browse related peptide mechanism research from Certified Peptide Solutions for compound documentation and research category context.
Key Takeaways
- BPC-157 is a synthetic 15-amino-acid peptide. Its sequence was derived from research on a body protection compound in gastric juice, but the peptide used in laboratory work is synthesized rather than isolated from a natural source.
- Research literature commonly refers to BPC-157 as a “stable gastric pentadecapeptide,” which distinguishes it from growth factors, hormones, copper peptides, mitochondrial peptides, and antimicrobial peptides.
- Published BPC-157 studies span gastrointestinal injury models, tendon and ligament repair, wound and burn models, angiogenesis, neurological injury, and inflammatory signaling, mostly in animal and cell-culture systems.
- The mechanisms most often cited in BPC-157 research include nitric oxide signaling, VEGF and VEGFR2 activity, FAK-paxillin cell adhesion signaling, angiogenesis, and gastric cytoprotection. These show up across different model categories rather than as one unified mechanism.
- Human evidence is limited, so preclinical findings don’t translate into human efficacy, recovery, treatment, or safety claims.
- Reliable study-count figures for BPC-157 should always carry a date and a reproducible database query, since the literature grows continuously and undated numbers go stale quickly.
How This Research Primer Differs From the Existing BPC-157 Overview
BPC-157 has two natural reading depths. The existing Certified Peptide Solutions BPC-157 overview covers what most readers want when they first encounter the compound: what it is, where it shows up in research, what risks come with it, and what its legal status looks like.
This primer skips that ground. The focus is on classification, sequence-level characteristics, cellular mechanisms, pathway analysis, experimental model design, methodology factors, and the limits of what published evidence can actually support. Researchers and advanced readers who already understand the basics will get more out of the technical depth here, while readers newer to BPC-157 will be better served by the overview first.
| Resource | Best For | Main Coverage |
| BPC-157 overview (companion article) | Readers new to the compound | What BPC-157 is, research areas, risks, legal considerations |
| BPC-157 research primer (this article) | Lab scientists, academic researchers, advanced readers | Classification, molecular characteristics, pathways, models, methodology, evidence limits |
Peptide Classification: What Kind of Compound Is BPC-157?
BPC-157 is a synthetic pentadecapeptide. That word breaks down cleanly: penta (five) plus deca (ten) plus peptide gives us a 15-amino-acid peptide. The full research label “stable gastric pentadecapeptide BPC 157” captures three things at once: the length, the historical origin in gastric juice research, and the compound’s behavior in laboratory settings.
Classification matters because BPC-157 keeps getting grouped with peptides it has no real relationship to. It is not a growth hormone secretagogue like sermorelin or ipamorelin. It is not a copper peptide like GHK-Cu or AHK-Cu. It is not a mitochondrial peptide like SS-31. And it is not a thymosin beta-4 fragment like TB-500. Each of those compounds has its own mechanism, its own research category, and its own interpretive framework. Importing assumptions from one family into another reliably produces wrong conclusions, which is why BPC-157 should be evaluated as its own category rather than as a generic “repair peptide.”
The “stable” part of the name is worth a second look. It refers to how the compound behaves in experimental conditions, including storage, handling, and analytical work. It is not a claim about persistence in a biological system or about safety in human use. Research terms carry specific meanings that don’t always survive translation into consumer-facing content.
| Classification Point | BPC-157 |
| Peptide class | Synthetic pentadecapeptide |
| Common research term | Stable gastric pentadecapeptide BPC 157 |
| Sequence length | 15 amino acids |
| Origin concept | Derived from research on a body protection compound associated with gastric juice |
| Primary research category | Preclinical cytoprotection and tissue repair models |
| Not related to | Growth hormone secretagogues, copper peptides, mitochondrial peptides, thymosin beta-4 fragments |
| Key interpretive note | Broad preclinical activity, limited human validation |
Origin and Molecular Characteristics of BPC-157
The conceptual origin of BPC-157 traces back to research on a body protection compound found in human gastric juice. Early work identified a sequence with apparent cytoprotective properties in animal models, and that sequence became the basis for what is now produced synthetically as BPC-157.
That distinction matters because it gets blurred constantly in consumer-facing material. The BPC-157 used in laboratories isn’t isolated from gastric juice. It is made through solid-phase peptide synthesis, the same way most modern research peptides are produced. The naturally occurring sequence is the inspiration. The research compound is synthetic.
Stable Gastric Pentadecapeptide Terminology
The standard research term breaks into three parts, and each part carries a specific meaning. “Pentadecapeptide” describes the length: 15 amino acids in sequence. “Gastric” reflects the historical link to gastric juice research and to early cytoprotection work on stomach injury models. “Stable” describes how the compound behaves in laboratory settings, which affects how studies handle storage, reconstitution, and analytical work. None of these descriptors says anything about how BPC-157 might behave in a human body, and treating “stable” as a safety claim or a persistence claim goes beyond what the term actually means in research literature.
Natural Origin Versus Synthetic Research Compound
Calling BPC-157 “naturally occurring” without qualification is technically wrong. The synthetic peptide used in studies is laboratory-produced, even though its sequence comes from research on a naturally sourced gastric protein. The cleanest accurate framing is that BPC-157 is a synthetic peptide derived from a naturally sourced sequence. That keeps the conceptual origin intact without overstating what’s actually in a researcher’s vial.
| Molecular Feature | Why It Matters |
| 15-amino-acid length | Places BPC-157 in the pentadecapeptide category |
| Gastric origin | Connects the compound to its historical role in cytoprotection research |
| Synthetic preparation | Important for reproducibility in laboratory settings |
| Stability in experimental conditions | Affects storage, handling, and analytical work |
| Broad activity across models | Each model carries its own interpretive boundaries |
| Limited human data | Findings don’t extend beyond preclinical territory |
Experimental Model Categories in BPC-157 Research
The BPC-157 literature covers a wider range of model categories than most peptides studied in the same era. Each category answers a different question, uses different endpoints, and carries its own interpretive boundaries. Pulling all of them together creates the illusion of a unified mechanism, but the honest read of the literature is that different studies are measuring different things in different systems.
Cell culture work, animal models, and the limited human reports each carry their own weight. The vast majority of evidence is preclinical, which means in vitro and animal data. That doesn’t make the work uninteresting. It just sets the ceiling on what conclusions the data can support, and researchers reading the literature should keep that ceiling visible.
| Model Category | Research Focus | Common Endpoints | Interpretation Limits |
| In vitro cell models | Cell migration, adhesion, survival, signaling | Migration assays, viability markers, pathway activation | Cell-level findings don’t extend to whole-organism behavior |
| Tendon and ligament models | Soft-tissue injury response | Tendon outgrowth, fibroblast activity, histology | Animal-based and model-specific |
| Gastrointestinal models | Gastric and intestinal injury response | Lesion scores, mucosal protection, inflammatory markers | The strongest preclinical base, but limited human confirmation |
| Wound and burn models | Skin injury and epithelial repair | Wound closure, epithelialization, angiogenesis | Animal models, not proof of human wound healing |
| Vascular models | Blood vessel response and endothelial activity | Angiogenesis, collateral vessel formation, NO signaling | Angiogenesis depends heavily on tissue context |
| Neurological models | Nerve, spinal cord, and brain injury | Functional scoring, tissue markers, neurotransmitter systems | Exploratory work, mostly preclinical |
| Inflammatory models | Tissue inflammation response | Cytokine markers, edema, tissue damage scores | Marker changes are not the same as anti-inflammatory therapy |
| Safety and tolerability | Model-specific safety observations | Toxicity signals, organ markers, behavior | Not equivalent to human safety data |
Review related peptide mechanism documentation for research-use peptide context.
Cellular Repair Mechanisms Studied With BPC-157
When BPC-157 shows up in repair-oriented research, the cellular endpoints typically fall into a handful of related categories: cell migration, adhesion, fibroblast activity, tendon cell outgrowth, endothelial response, and cytoprotection. Each is a specific assay or model with a specific question attached, not a generic claim about “tissue repair.” Reading the cellular mechanism literature accurately means tying each finding to the assay it came from.
Cell Migration and Adhesion
Cells need to move into damaged areas for repair processes to start. Wound assays, scratch assays, and transwell migration tests all measure how cells respond when they’re displaced or when a gap opens in a layer of cells. BPC-157 has been studied in connection with migration in these kinds of assays, with researchers often citing FAK-paxillin signaling as part of the proposed mechanism. FAK (focal adhesion kinase) and paxillin sit at the intersection of how cells attach to the extracellular matrix and how that attachment translates into movement.
A faster migration result in a culture dish answers a specific question, but it does not translate cleanly into human tissue healing. The interpretation has to stay tied to the assay, not stretched across the boundary into clinical claims.
Fibroblast and Tendon Cell Activity
Fibroblasts are the workhorses of extracellular matrix biology. They produce collagen and the broader matrix scaffold that supports soft tissue, which is why they show up repeatedly in tendon, ligament, and skin repair research. Tendon outgrowth assays, where tendon-derived cells extend or migrate from tissue explants, are common in soft-tissue work because they capture both migration and matrix-related behavior at once.
BPC-157 research in this space has examined fibroblast activity and tendon cell behavior in laboratory models. Findings about fibroblasts in culture, or about tendon cells in an explant assay, are research observations in those specific systems. They aren’t evidence for collagen production in humans or for tendon healing in clinical settings.
Endothelial Response and Angiogenesis
Endothelial cells line blood vessels, and angiogenesis is the formation of new vessels. The BPC-157 literature touches angiogenesis often, partly because VEGF (vascular endothelial growth factor) and its receptor VEGFR2 keep showing up in pathway analyses, and partly because angiogenesis is central to many repair processes.
One nuance gets dropped a lot in casual peptide content. Angiogenesis isn’t automatically a good thing. In some tissues and some contexts, new vessel formation supports healing. In others, like tumor biology or certain eye conditions, angiogenesis is exactly what researchers want to suppress. The same biological process can be a positive or a problematic finding depending on what’s being studied.
| Cellular Process | Why It Matters | How to Read the Result |
| Cell migration | Relevant to wound, tendon, and tissue repair models | Migration in a dish does not equal clinical repair |
| Cell adhesion | Part of how cells organize within tissue | Pathway-specific evidence is needed |
| Fibroblast activity | Central to extracellular matrix biology | Not equivalent to evidence for human collagen production |
| Tendon cell outgrowth | Used in tendon and ligament models | Preclinical and explant-based |
| Endothelial response | Tied to vascular repair and angiogenesis | Highly context-dependent |
| Angiogenesis | Vessel formation in repair models | Not automatically beneficial; depends on tissue and timing |
| Cytoprotection | Shows up in gastric and injury models | Preclinical, not a human protection therapy |
Pathway Analysis: Biological Systems Associated With BPC-157
The pathway literature on BPC-157 is varied. Different studies emphasize different signaling systems, and no single mechanism has been established as the unified explanation for the broad range of activities observed across models. That is exactly what researchers would expect from a compound studied across so many different tissues, injury types, and endpoints: different systems engage different signaling layers.
The pathways below appear most often in published BPC-157 work. Each one connects to specific kinds of research models. When reading a paper, the question worth asking is whether the study actually tested the pathway directly or whether it referenced the pathway as background context.
| Pathway or System | Where It Shows Up | What the Research Reports |
| Nitric oxide system | Vascular tone, endothelial response, blood flow, cytoprotection | BPC-157 has been associated with NO signaling in vascular and cytoprotective models |
| VEGF and VEGFR2 | Angiogenesis and endothelial activity | Appears in angiogenesis-focused BPC-157 studies |
| FAK-paxillin signaling | Cell adhesion, migration, tendon outgrowth | Connected to migration-related findings in specific models |
| Angiogenesis | Vessel growth and vascular repair models | Interpreted by model and tissue context |
| Fibroblast signaling | Extracellular matrix and soft-tissue models | Cellular-level findings, not human recovery evidence |
| Inflammatory signaling | Injury and tissue damage models | Marker changes; not equivalent to anti-inflammatory therapy |
| Dopaminergic systems | Neurological and behavioral models | Separate research domain from tissue repair work |
| Serotonergic systems | Gut-brain and neurological models | Limited direct study support |
| Gastrointestinal cytoprotection | Gastric and mucosal injury models | The historical foundation of BPC-157 research |
Methodology Considerations for Interpreting BPC-157 Studies
Methodology is where the difference between a useful BPC-157 finding and a misleading one usually lives. Two studies that both look “positive” can be measuring entirely different things: different species, different doses, different routes, different time windows, and different control groups. Whether the results actually mean the same thing depends on the experimental design more than on the conclusion section.
The variables below are the main axes along which BPC-157 studies vary. Walking through them when reading a paper makes it easier to tell whether a claim is supported by what was tested or whether it is an extrapolation beyond what the data covers.
| Methodology Factor | Why It Matters |
| Species | Rodent, rabbit, and other models do not translate directly to humans |
| Model type | GI, tendon, vascular, neurological, and wound models test different endpoints |
| Route of administration | Route affects exposure and tissue distribution |
| Dose | Experimental dose shapes interpretation and is not dosing guidance |
| Timing window | Acute and longer-duration models answer different questions |
| Comparator group | Vehicle, untreated control, or active comparator changes the reading |
| Endpoint selection | Histology, biomarkers, function scores, and lesion scores are not equivalent |
| Replication | Single-model findings need confirmation before generalization |
| Human relevance | Preclinical findings need clinical validation before therapeutic claims |
Explore related peptide mechanism research for lab-focused peptide evaluation.
How Many Studies Have Been Published on BPC-157?
The honest answer is that the number changes constantly, depends on the database, and depends on how the search is defined. Study counts cited in older content drift quickly as new work is published, and an undated count is rarely useful for anyone trying to verify or update the figure.
Some categories of BPC-157 research are well-developed, others are emerging, and a few are still mostly hypothesis-driven.
| Database | Suggested Query | What It Covers |
| PubMed | “BPC 157” OR “BPC-157” OR “pentadecapeptide BPC 157” | Indexed biomedical literature |
| Google Scholar | “BPC 157” | Broader scope, includes duplicates, patents, and non-peer-reviewed material |
| ClinicalTrials.gov | “BPC-157” | Registered human trials |
| WADA and regulatory sources | “BPC-157” | Legal and sports-status context |
The distribution of BPC-157 literature by research domain looks something like this. Gastrointestinal research forms the historical foundation, with the oldest and deepest body of work. Tendon and ligament research is preclinical and growing. Vascular, wound, neurological, muscle and orthopedic, and safety research each occupy their own corners with their own interpretive needs.
| Research Category | What Studies Examine | Where the Evidence Sits |
| GI injury research | Gastric lesions, intestinal injury, mucosal protection | The historical foundation; the oldest and deepest area |
| Tendon and ligament research | Tendon outgrowth, ligament healing, fibroblast activity | Strongly preclinical, growing |
| Vascular research | Angiogenesis, NO signaling, endothelial activity | Mechanistic and model-dependent |
| Wound and burn research | Epithelial closure, tissue integrity, angiogenesis | Animal-based, not proof of human wound healing |
| Neurological research | Spinal cord injury, brain injury, neurotransmitter systems | Exploratory, preclinical |
| Muscle and orthopedic models | Muscle injury, bone, joint, and soft-tissue endpoints | Newer and more variable |
| Safety and pharmacology | Tolerability, ADME, organ markers, behavior | Preclinical, not equivalent to full human safety data |
Evidence Limitations: What BPC-157 Research Can and Cannot Prove
The limits of BPC-157 evidence are part of the story, not a footnote. Most of the published work supports discussion of preclinical activity, pathway hypotheses, and model-specific biological responses. That is a real evidence base, and it gives researchers a foundation for further investigation. What it isn’t is proof of human tissue repair, injury recovery, safety, or therapeutic efficacy.
A useful framing here is the distinction between three layers: biological plausibility, preclinical activity, and clinical validation. BPC-157 has biological plausibility for several proposed mechanisms based on the in vitro and animal work. It has preclinical activity in a range of model systems. It has limited clinical validation. Those three layers are very different in what they can support, and treating preclinical findings as if they had clinical-level weight is the most common error in BPC-157 content outside the actual research literature.
| Evidence Level | What It Supports | What It Doesn’t Support |
| In vitro data | Cellular behavior, pathway signals, early mechanism hypotheses | Whole-organism effects or clinical outcomes |
| Animal data | Model-specific tissue, vascular, GI, or neurological responses | Human efficacy or safety |
| Biomarker data | Pathway activity, biological response | Direct patient benefit |
| Small human reports | Early clinical interest, if available | Broad efficacy or safety conclusions |
| Review articles | Synthesis of existing literature | New evidence on their own |
| Supplier or clinic content | Search-term context only | Mechanism, safety, or efficacy claims |
BPC-157 Compared With Other Mechanism-Focused Peptide Research
BPC-157 sits in the tissue repair and cytoprotection research category, but the broader peptide research landscape includes several adjacent categories that get confused with it. Knowing where the boundaries fall makes it easier to read the literature accurately and avoid importing mechanism assumptions from one peptide family into another.
TB-500, GHK-Cu, SS-31, and KPV each anchor a different research conversation. TB-500 is a thymosin beta-4 fragment tied to actin dynamics and cell migration. GHK-Cu is a copper peptide associated with collagen and extracellular matrix research. SS-31 is a mitochondrial peptide focused on inner-membrane targeting and cardiolipin stabilization. KPV is a tripeptide studied for NF-kB pathway interaction in inflammation models. None of these shares BPC-157’s mechanism, even where their research domains overlap on the surface.
| Peptide or Stack | Research Category | How It Differs From BPC-157 |
| BPC-157 | Stable gastric pentadecapeptide / tissue repair | The compound this article covers |
| TB-500 | Thymosin beta-4 fragment | Built around actin binding and cell migration |
| GHK-Cu | Copper peptide | Associated with collagen, skin, and extracellular matrix biology |
| SS-31 | Mitochondrial peptide | Targets the inner mitochondrial membrane and cardiolipin |
| KPV | Anti-inflammatory tripeptide | Focused on NF-kB signaling in inflammation models |
| Glow stack | Multi-compound research formulation | Combines GHK-Cu, BPC-157, and TB-500 at the stack level |
| Klow stack | KPV-containing research stack | Adds KPV to the Glow formulation for an anti-inflammatory pathway |
The closest peptide for direct comparison is TB-500, since both are studied in tissue repair contexts even though their mechanisms diverge. The BPC-157 and TB-500 mechanisms article handles that comparison in detail. For a different peptide category entirely, the SS-31 peptide mechanism of action guide covers mitochondrial peptide work, and the Glow peptide stack components article shows how BPC-157 shows up at the stack level alongside other compounds.
Read related peptide mechanism guides to compare BPC-157 with TB-500, SS-31, GHK-Cu, KPV, and research stack profiles.
Research-Use and Safety Framing for BPC-157
BPC-157 is a research-use compound. This article doesn’t provide dosing, administration, injection, cycling, or stacking guidance, and readers looking for that kind of content should consult sources qualified to give it. Human safety evidence for BPC-157 remains limited, so blanket statements like “BPC-157 is safe” or “BPC-157 is well tolerated” overstate what the available data can actually support.
Sports and regulatory status varies by jurisdiction and by governing body. WADA includes BPC-157 on its prohibited list for sport. The compound is not FDA-approved for human use. Anyone working in this space should verify the current status against current sources rather than assuming last year’s information still holds.
The framing language used around BPC-157 matters because consumer-facing material often slips into clinical-sounding claims that don’t match the research record. The table below pairs common claims with what the research actually supports.
| Common Claim | What the Research Supports |
| BPC-157 heals tissue | BPC-157 has been studied in tissue repair models |
| BPC-157 repairs tendons | BPC-157 appears in tendon and ligament research models |
| BPC-157 promotes recovery | BPC-157 has been examined in preclinical injury endpoints |
| BPC-157 is naturally occurring | BPC-157 is a synthetic peptide derived from a naturally sourced gastric sequence |
| BPC-157 is safe | Human safety evidence remains limited |
| BPC-157 activates repair pathways | BPC-157 is associated with repair-related pathways in specific model systems |
| BPC-157 should be used for injury repair | Preclinical findings do not constitute use or treatment guidance |
For administration-risk questions that go beyond mechanism, the BPC-157 injection safety article covers those specifically.
Expert Viewpoint: How Researchers Should Approach BPC-157 Literature
BPC-157 has one of the broader preclinical footprints in modern peptide research, and that breadth is both its strength and its biggest interpretive trap. The literature spans gastrointestinal, tendon, ligament, vascular, neurological, wound, and inflammatory models, which makes it easy to assume the compound has a unified repair mechanism that operates across all of them. The data doesn’t support that read. What it supports is the more modest observation that BPC-157 has been examined in many different models, with different endpoints, often producing study-specific findings that don’t generalize cleanly across boundaries.
The strongest evidence base sits in the gastrointestinal cytoprotection work, which traces back to the original gastric juice research that gave the compound its name. That foundation is solid as preclinical work goes. Tendon and ligament research has grown substantially and produces consistent enough signals to keep researchers interested, but it remains animal-based.
The vascular and angiogenesis work is mechanistically interesting because it ties into VEGF and VEGFR2 signaling, but angiogenesis itself is not universally beneficial, and researchers should read each angiogenesis finding by tissue and by context rather than as a generic positive.
Human evidence is where the picture gets thin. The available human work is small in scale and limited in scope, which is why the gap between “preclinical activity” and “clinical validation” matters so much for this compound. Consumer-facing content tends to collapse that gap, treating animal findings or in vitro signals as if they were equivalent to human therapeutic evidence. The honest research read keeps those layers separate.
For laboratory work, the integrity of any BPC-157 study depends on the integrity of the input compound. HPLC purity at or above 99%, mass spectrometry identity confirmation, and batch-level certificates of analysis from independent U.S. laboratories form the practical floor for reference-grade material. Without that documentation, study outcomes carry variability that no amount of careful design can fully correct for after the fact.
View related Certified Peptide Solutions research content for compound documentation, testing details, and peptide category context.
Frequently Asked Questions
What type of research compound is BPC-157?
BPC-157 is a synthetic 15-amino-acid gastric pentadecapeptide studied mainly in preclinical tissue repair, gastrointestinal, vascular, wound, neurological, and inflammatory models. It is not a growth hormone secretagogue, copper peptide, mitochondrial peptide, or thymosin beta-4 fragment.
Is BPC-157 naturally occurring or synthetic?
The research compound is synthetic. The sequence was derived from a naturally sourced gastric protein, but the peptide used in studies is laboratory-produced through solid-phase synthesis, not isolated from a natural source.
What cellular mechanisms are studied with BPC-157?
Cell migration, adhesion, tendon cell outgrowth, fibroblast activity, endothelial response, angiogenesis, and cytoprotective processes. Findings are tied to specific assays or models rather than to whole-organism repair.
Which pathways appear in BPC-157 research?
Nitric oxide signaling, VEGF and VEGFR2 activity, FAK-paxillin signaling, angiogenesis, inflammatory-response models, and gastrointestinal cytoprotection. These show up across different model categories rather than as a unified mechanism of action.
What experimental models are used in BPC-157 studies?
In vitro cell models, animal tendon and ligament models, gastrointestinal injury models, wound and burn models, vascular models, neurological injury models, and inflammatory models. Each system answers a different mechanistic question.
How many BPC-157 studies have been published?
As of [INSERT DATE], a PubMed search for “BPC 157” OR “BPC-157” OR “pentadecapeptide BPC 157” returned [INSERT COUNT] results. The figure should be updated whenever the article is revised.
What do BPC-157 studies cover?
Gastrointestinal injury, tendon and ligament models, wound repair, angiogenesis, vascular response, neurological injury, inflammatory models, and safety or pharmacology endpoints. The literature is distributed unevenly across these categories.
Can BPC-157 preclinical findings be applied directly to humans?
No. Preclinical findings can support mechanistic hypotheses and model-specific interpretation, but they do not prove human efficacy, safety, injury recovery, or therapeutic benefit.
How should researchers interpret BPC-157 pathway findings?
By model type, species, endpoint, route, dose, timing window, comparator group, and replication strength. Generalizing across models without supporting evidence at each step is where most overstatement enters the conversation.